Lynx Biosciences, Inc.

Lynx Biosciences, Inc. develops innovative biotech solutions using a proprietary ex vivo disease biology platform, focusing on drug discovery in immuno-oncology and immunology. Lynx Biosciences, Inc. , founded in 2015, is a biotech firm based in San Diego, US, specializing in advanced technologies for drug discovery.

The company was founded by Chorom Pak, who has a history of entrepreneurial ventures. Lynx Biosciences has engaged in three strategic deals, with the most recent occurring on November 3, 2021. Lynx Biosciences, Inc. (LynxBio) specializes in innovative biotech solutions centered around their proprietary ex vivo disease biology platform, which integrates a multi-omic approach to drug discovery in immuno-oncology and immunology.

The core offerings include advanced technologies that leverage single-cell and spatial analysis to provide deep insights into tumor-immune interactions, enabling the identification and validation of druggable targets. By utilizing sophisticated primary patient models, LynxBio aims to streamline the development of next-generation therapies, expediting their journey from discovery to clinical application. Their services cater primarily to biopharmaceutical companies, research institutions, and collaborative partners engaged in drug development, particularly in the United States and Europe, where there is a strong demand for therapeutic candidates targeting complex diseases. LynxBio’s revenue structure is primarily derived from strategic partnerships and collaborations with leading biopharmaceutical firms, focusing on the development of novel therapeutic candidates.

The transactions are structured around B2B partnerships, wherein LynxBio provides its proprietary insights and data-driven services in exchange for funding and shared intellectual property rights. These collaborations are designed to facilitate access to LynxBio’s unique platform, which enhances the translatability of research findings into clinical applications. The company’s revenue generation is further supported by its internal pipeline of therapies targeting immune cell interactions and tumor microenvironments, although specific pricing plans and transaction values are not publicly disclosed. In November 2021, Lynx Biosciences, Inc.

raised an undisclosed amount of Seed funding led by new investor Checkmate Capital, with participation from Great Oaks Venture Capital and returning investors including The Cove Fund and WARF Ventures. The company plans to utilize this funding to develop its MicroC3 platform for oncological treatment and research, aiming to enhance the development of targeted therapies. The strategic focus includes expanding its market presence within the United States and Europe by late 2023.